

## NOTIFICATION TO STOCK EXCHANGE

### COMPANY STATEMENT

## **Biocon Biologics Launches Nepexto<sup>®</sup>, a Biosimilar to Enbrel<sup>®</sup> (Etanercept), in Australia**

***Bengaluru, Karnataka, India, July 23, 2025***

**Biocon Biologics Ltd (BBL)**, a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today it has launched Nepexto<sup>®</sup>, a biosimilar to the reference product Enbrel<sup>®</sup> (Etanercept), in Australia. Nepexto<sup>®</sup> will be promoted by Generic Health, our local partner and a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, to expand access to patients in Australia.

Etanercept is a fusion-protein that inhibits tumor necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.

Since receiving EU marketing authorization in 2020, Nepexto<sup>®</sup> has earned broad adoption across Europe. Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto<sup>®</sup> into new markets worldwide and further strengthen our immunology offering.

*– Company Spokesperson*

Nepexto<sup>®</sup> is a registered trademark of Biosimilars New Co Limited, a Biocon Biologics Company. All other trademarks are the property of their respective owners.